Clinical Insights August 21, 2026

Dense Breast Tissue and ABUS: What Women Should Know

Learn what BI-RADS density categories A–D mean, why Category B can still merit discussion, and how ABUS may support screening access for younger women.

Breast density has moved from a specialized radiology term into a national conversation about breast health. Since September 10, 2024, mammography facilities across the United States have been required to tell patients whether their breasts are dense and explain that dense tissue can make cancer harder to find on a mammogram.

That notification is important, but it is only the beginning of the conversation.

Dense breast tissue is common, particularly among younger women. It can reduce the visibility of some cancers on mammography and is itself associated with increased breast cancer risk. For women and imaging providers, the practical question is what to do with that information—and when supplemental imaging such as automated breast ultrasound may be appropriate.

What Is Dense Breast Tissue?

Breasts contain fatty tissue, glandular tissue, and fibrous connective tissue. Breast density describes the relative amount of fibrous and glandular tissue compared with fatty tissue as seen on a mammogram.

Radiologists classify breast density using four BI-RADS categories:

Almost entirely fatty

Mammography can generally see through the tissue more readily.

Scattered fibroglandular density

Some areas of dense tissue are present, but the breast is officially classified as “not dense.”

Heterogeneously dense

Dense tissue may obscure small masses.

Extremely dense

Dense tissue lowers the sensitivity of mammography.

Under the current BI-RADS and federal reporting framework, Categories C and D are considered “dense,” while Categories A and B are considered “not dense.” Breast density cannot be determined reliably by touch, breast size, or outward appearance. It is an imaging finding assessed by a radiologist.

Is Category B Really the End of the Density Conversation?

Officially, Category B is not classified as dense. Clinically, however, breast density behaves more like a continuum than a switch that turns on only when a woman crosses from Category B to Category C.

Category B covers a broad range—from a few isolated areas of fibroglandular tissue to more substantial scattered tissue. Depending on its amount and location, that tissue may still overlap an important area of the mammogram. Research using quantitative measurements has found a continuous relationship between increasing density and declining mammographic sensitivity, suggesting that a four-category label cannot capture every woman’s individual masking risk.

That does not mean every woman with Category B density needs supplemental imaging, nor does it change the official definition of “dense breasts.” It does mean Category B should not automatically end the conversation. A woman near the B–C boundary—or one who has additional risk factors—may reasonably ask her healthcare provider whether the distribution of her tissue, family history, age, prior findings, and overall risk warrant a more individualized screening discussion.

The more useful question may be broader than “Am I officially dense?” It may be: “Could my breast tissue or personal risk make a cancer harder to see, and would another imaging method add useful information?”

Dense breasts are not abnormal or a disease. They are, however, clinically important for two separate reasons: dense tissue can make mammograms more difficult to interpret, and it is associated with a higher risk of developing breast cancer.

How Common Are Dense Breasts?

The National Cancer Institute reports that nearly half of women age 40 and older who undergo mammography are found to have dense breasts. An NCI evidence review estimates that approximately 43% of women ages 40–74 have heterogeneously or extremely dense tissue.

Breast density generally declines with age, which makes the issue particularly relevant for younger women. A large U.S. prevalence study estimated that 27.6 million women ages 40–74 had dense breasts and that women ages 40–49 represented 44.3% of that population.

These numbers help explain why breast density is not a niche issue. It affects millions of women at the same time they are beginning routine screening or considering how their personal risk should shape a screening plan.

Why Dense Tissue Can Make Mammography More Challenging

Mammography remains the most effective primary breast cancer screening method for most women. It can identify cancers before they can be seen or felt and has an essential role in early detection.

Dense tissue creates a visibility challenge because dense tissue and many cancers both appear white on a mammogram. Fatty tissue appears darker. A cancer can therefore be more difficult to distinguish when it is surrounded by dense tissue—an effect sometimes compared with trying to find a snowball in a snowstorm.

The NCI reports that high breast density is associated with a 10–29 percentage-point reduction in mammographic sensitivity. In plain language, mammography is more likely to miss a cancer in dense breasts than in breasts that contain more fatty tissue.

This does not mean mammography has no value for women with dense breasts. It means density should be considered alongside age, family history, genetic factors, prior biopsies, personal medical history, and other risk factors when a woman and her healthcare provider discuss screening.

What the National Breast-Density Rule Changed

The FDA’s updated Mammography Quality Standards Act regulations took effect on September 10, 2024. Mammography reports must now classify breast density, and patient summaries must explain whether the tissue is dense or not dense.

For patients with dense breasts, the required notification explains that:

Dense tissue can make it harder to find breast cancer on a mammogram.
Dense tissue also raises the risk of developing breast cancer.
In some people, imaging tests in addition to mammography may help find cancers.
Patients should discuss breast density, overall risk, and their individual situation with a healthcare provider.

The federal rule gives every mammography patient a consistent baseline of information. It does not prescribe the same supplemental test for every woman, because density is only one part of an individualized risk assessment.

Where Automated Breast Ultrasound May Fit

Automated breast ultrasound, or ABUS, creates standardized three-dimensional ultrasound volumes of the breast. Unlike mammography, ultrasound does not use ionizing radiation. Unlike handheld ultrasound, an automated system separates image acquisition from interpretation and produces a reproducible volumetric examination that a radiologist can review after the scan.

ABUS is designed to provide additional information about breast tissue. Because ultrasound and mammography depict tissue differently, ultrasound may reveal findings that are difficult to distinguish on mammography in some women with dense breasts.

A recent systematic review and meta-analysis reported that adding ABUS to mammography increased sensitivity by 6–35 percentage points and detected approximately 2.4–4.3 additional cancers per 1,000 women with dense breasts. The review also found higher recall rates and modest reductions in specificity, underscoring an important reality: supplemental screening can find additional cancers, but it can also lead to more follow-up imaging and benign biopsies.

That tradeoff is why the decision should be individualized rather than reduced to a single statistic.

Why Breast Screening Matters for Younger Women

Younger women are more likely to have dense tissue, yet many do not begin routine mammography until age 40 and may not know their breast density before their first mammogram. Some younger women also face additional concerns, including a family history of breast cancer, genetic risk, prior chest radiation, symptoms, implants, or anxiety about a change in the breast.

No single screening pathway is right for every younger woman. Symptoms such as a new lump, nipple discharge, skin changes, or persistent focal pain require medical evaluation and should not be handled as routine screening. Women at increased risk may need earlier or different imaging based on professional guidelines and consultation with a clinician.

The broader access gap remains real: younger women may want to understand their options but encounter referral requirements, unfamiliar technology, limited appointment availability, or screening environments that feel intimidating.

How Eve Wellness Is Expanding Screening Access

Eve Wellness in San Francisco is demonstrating a new model for making advanced breast ultrasound screening more accessible and patient-centered.

Eve provides automated breast ultrasound in a comfortable setting designed around the screening experience. According to Eve, appointments do not require a physician referral, the scan takes approximately 15–20 minutes, and the examination is interpreted by a physician, with results generally returned within a few days.

The model is especially relevant to younger women because ABUS uses no ionizing radiation and Eve offers access to adults below the usual age for routine mammography. Eve combines:

Invenia™ Automated Breast Ultrasound acquisition
QView Medical’s FDA-approved QVCAD artificial intelligence
Trained acquisition personnel
Physician interpretation
Defined pathways for follow-up when a finding requires additional evaluation

QVCAD supports ABUS interpretation by analyzing the three-dimensional dataset and highlighting areas that may warrant attention. It does not independently diagnose cancer or replace the physician. The radiologist reviews the complete examination and makes the final clinical assessment.

Eve’s approach illustrates how technology, clinical oversight, and a more approachable environment can work together to reduce barriers. It gives younger women another point of access to breast health information while maintaining physician interpretation at the center of care.

Supplemental Breast Screening Is Not One-Size-Fits-All

ABUS is not a universal replacement for mammography, MRI, diagnostic ultrasound, or clinical evaluation. The appropriate approach depends on the individual.

Women considering supplemental screening should ask:

Do I know my breast-density category?
What is my overall breast cancer risk—not just my density?
Is this examination for routine screening or evaluation of a symptom?
What are the potential benefits, false-positive risks, and follow-up steps?
Who will interpret the examination?
What happens if the screening identifies an area that needs more evaluation?

Screening works best as a connected clinical process, not as an isolated scan.

From Breast-Density Awareness to Informed Action

The national density-notification requirement has given more women essential information about their breast tissue. The next step is ensuring they have access to understandable guidance, appropriate imaging options, qualified interpretation, and reliable follow-up.

For younger women, that conversation may begin before routine mammography. For women with dense breasts, it may begin when a mammography report raises questions about what additional screening could contribute.

Automated breast ultrasound is one option in that evolving landscape. When combined with trained personnel, physician interpretation, responsible AI, and an appropriate follow-up pathway, it can help expand access to information that supports earlier and more confident care.

Interested in learning how QVCAD supports ABUS interpretation? Explore the QView platform or contact QView Medical.

Frequently Asked Questions About Dense Breasts and ABUS

Which BI-RADS categories are considered dense breasts?

BI-RADS Categories C and D are officially classified as dense. Categories A and B are classified as not dense, although Category B can include meaningful scattered fibroglandular tissue and density exists on a continuum.

Should women with Category B breast density consider supplemental screening?

Category B alone does not mean supplemental imaging is needed. Women near the B–C boundary or those with other risk factors can ask a healthcare provider whether tissue distribution and their overall risk warrant a more individualized screening discussion.

What is automated breast ultrasound?

Automated breast ultrasound, or ABUS, creates standardized three-dimensional ultrasound volumes for physician interpretation. It uses no ionizing radiation and may provide additional information in some women with dense breast tissue.

Does ABUS replace mammography?

No. ABUS is not a universal replacement for mammography. The appropriate screening approach depends on age, density, symptoms, family history, genetic factors, and other individual risks.

Can younger women receive screening at Eve Wellness?

Eve Wellness offers referral-free automated breast ultrasound access to adults, including women below the usual age for routine mammography. A physician interprets each examination, and appropriate clinical follow-up remains essential.